Rituximab-arrx (Riabni)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.

General information

Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in FDA indication

To be completed

Also known as

  • Code name: ABP-798
  • Brand name: Riabni

References

  1. ↑ Rituximab (Rituxan) patient drug information (Chemocare)
  2. ↑ Rituximab (Rituxan) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Rituximab-arrx_(Riabni)&oldid=97760"